This trial is evaluating whether Sintilimab will improve 1 primary outcome and 5 secondary outcomes in patients with Locally Advanced Undifferentiated Pleomorphic Sarcoma. Measurement will happen over the course of At 12 weeks.
This trial requires 25 total participants across 1 different treatment group
This trial involves a single treatment. Sintilimab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Sarcoma survivors have higher than expected mortality throughout the course of their lives. This is likely due to a combination of factors including late diagnosis, poor quality of life, and dilation of tumor channels resulting in increased pressure in the extremity, and systemic side effects of chemotherapy. Survival rates appear to improve with earlier diagnoses, good quality of life, and early intervention with new adjuvant therapies. Patients who survive more than 5 years of treatment have slightly better outcomes than those who do not complete their full course of treatment in terms of local control and disease free survival. Survival rates were independent of age group and histologic subtype." - Anonymous Online Contributor
"Although NCS is the standard of care for patients with sarcoma, there is still significant room for improvement. Further research is needed to determine if more aggressive treatment of sarcoma patients is warranted." - Anonymous Online Contributor
"A recent analysis of all published clinical trials of sintilimab showed that the most frequent adverse events included fever (59%), headache (44%), fatigue (33%), nausea (27%), rash (23%), dizziness (20%), weight gain (18%), arthralgia/arthritis (17%), vomiting (12%), dyspnoea (11%), leucopenia (8%), thrombocytopenia (5%), anaemia (4%) and cough (4%)." - Anonymous Online Contributor
"Sintilimab is a monoclonal antibody against CD25 and is approved by FDA for treating patients with relapsed or refractory cutaneous T-cell lymphoma and B-cell chronic lymphocytic leukaemia in combination with rituximab. The primary indication for sintilimab was marketed by Bristol-Myers Squibb Corporation.\n" - Anonymous Online Contributor
"In patients with relapsed or refractory Hodgkin disease, sintilimab is commonly used as monotherapy. However, due to its intrinsic toxicity profile, appropriate use of sintilimab monotherapy should be restricted to specialized centers." - Anonymous Online Contributor
"Patients with poor performance status, large lesions, facial involvement, high grade histology or advanced disease present a very poor prognosis in terms of cure. Even patients with minimal residual disease after surgery may still relapse." - Anonymous Online Contributor
"The incidence of [soft tissue sarcoma](https://www.withpower.com/clinical-trials/soft-tissue-sarcoma) varies in the population between 0.8% and 1.4%, with a male predominance. A peak incidence occurs in males over 70 years of age. We report a significant increase in incidence since the 1970s, probably as a result of increased exposure to tobacco, pesticides and asbestos. The risk of developing soft tissue sarcoma appears to be greater after radiation therapy. In addition to chemical carcinogens, UV light is also considered to play an important role in causation of sarcoma. This may be due to a dose threshold effect. All benign conditions are excluded from the study, including those related to local trauma or a prior history of malignancy, so no confounding effect is observed." - Anonymous Online Contributor
"Sintilimab showed superiority over placebo, especially in patients with advanced melanoma. Findings from a recent study confirms previous results in patients with metastatic melanoma. Further randomized controlled studies are now warranted." - Anonymous Online Contributor